Keros Therapeutics (KROS) Competitors $15.55 -0.11 (-0.70%) Closing price 04:00 PM EasternExtended Trading$15.54 -0.01 (-0.03%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. ALVO, TARS, CPRX, CGON, IBRX, IDYA, OCUL, DNLI, CNTA, and MLYSShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Alvotech (ALVO), Tarsus Pharmaceuticals (TARS), Catalyst Pharmaceuticals (CPRX), CG Oncology (CGON), ImmunityBio (IBRX), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Denali Therapeutics (DNLI), Centessa Pharmaceuticals (CNTA), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Alvotech Tarsus Pharmaceuticals Catalyst Pharmaceuticals CG Oncology ImmunityBio IDEAYA Biosciences Ocular Therapeutix Denali Therapeutics Centessa Pharmaceuticals Mineralys Therapeutics Keros Therapeutics (NASDAQ:KROS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Do analysts rate KROS or ALVO? Keros Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 92.93%. Alvotech has a consensus price target of $14.00, suggesting a potential upside of 72.41%. Given Keros Therapeutics' higher possible upside, research analysts clearly believe Keros Therapeutics is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Alvotech 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders hold more shares of KROS or ALVO? 71.6% of Keros Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, KROS or ALVO? Keros Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Which has higher earnings and valuation, KROS or ALVO? Keros Therapeutics has higher earnings, but lower revenue than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M177.93-$187.35M$0.3150.16Alvotech$491.98M4.98-$231.86M$0.2335.30 Is KROS or ALVO more profitable? Alvotech has a net margin of 11.26% compared to Keros Therapeutics' net margin of 8.06%. Keros Therapeutics' return on equity of 2.96% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics8.06% 2.96% 2.74% Alvotech 11.26%-38.36%9.28% Does the media favor KROS or ALVO? In the previous week, Keros Therapeutics had 1 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Keros Therapeutics and 3 mentions for Alvotech. Alvotech's average media sentiment score of 1.39 beat Keros Therapeutics' score of 1.20 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKeros Therapeutics beats Alvotech on 11 of the 15 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$636.04M$3.15B$5.79B$10.18BDividend YieldN/A2.33%5.73%4.61%P/E Ratio50.1621.2474.8626.40Price / Sales177.93464.25543.29125.95Price / CashN/A44.4425.8129.91Price / Book1.109.6413.256.28Net Income-$187.35M-$53.20M$3.29B$270.38M7 Day Performance0.52%0.44%0.47%2.70%1 Month Performance7.39%4.26%4.60%5.99%1 Year Performance-72.71%9.43%73.42%25.94% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.3331 of 5 stars$15.55-0.7%$30.00+92.9%-72.5%$636.04M$3.55M50.16100Positive NewsALVOAlvotech3.7607 of 5 stars$8.05+1.2%$14.00+74.0%-25.7%$2.43B$491.98M34.981,032Short Interest ↓TARSTarsus Pharmaceuticals2.5007 of 5 stars$57.18-0.9%$66.67+16.6%+48.4%$2.41B$295.52M-24.5250Positive NewsCPRXCatalyst Pharmaceuticals4.9551 of 5 stars$19.65-0.7%$33.20+69.0%-1.2%$2.40B$491.73M11.9180Positive NewsAnalyst DowngradeCGONCG Oncology2.396 of 5 stars$30.82+7.5%$54.30+76.2%-4.2%$2.35B$551K-17.4161Analyst ForecastInsider TradeGap UpIBRXImmunityBio2.506 of 5 stars$2.39+0.6%$10.75+350.7%-27.4%$2.25B$14.74M-4.97590IDYAIDEAYA Biosciences3.9675 of 5 stars$25.58-0.7%$45.77+79.0%-34.3%$2.25B$7M-6.7680Positive NewsAnalyst ForecastOCULOcular Therapeutix4.016 of 5 stars$12.62-2.5%$17.20+36.3%+42.3%$2.20B$63.72M-9.88230News CoverageAnalyst ForecastDNLIDenali Therapeutics4.3611 of 5 stars$14.95-2.3%$33.62+124.8%-53.9%$2.19B$330.53M-5.34430Positive NewsCNTACentessa Pharmaceuticals3.13 of 5 stars$15.86-0.3%$31.45+98.4%+28.4%$2.12B$6.85M-8.86200Insider TradeMLYSMineralys Therapeutics3.18 of 5 stars$31.90+9.1%$36.60+14.7%+215.5%$2.11BN/A-8.9628Positive NewsGap Down Related Companies and Tools Related Companies Alvotech Alternatives Tarsus Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives CG Oncology Alternatives ImmunityBio Alternatives IDEAYA Biosciences Alternatives Ocular Therapeutix Alternatives Denali Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts